540359 PARMAX

Parmax Pharma Share Price

 

 

Start SIP in PARMAX

Start SIP

Performance

  • Low
  • ₹34
  • High
  • ₹35
  • 52 Week Low
  • ₹28
  • 52 Week High
  • ₹55
  • Open Price₹34
  • Previous Close₹33
  • Volume797
  • 50 DMA₹33.83
  • 100 DMA₹34.24
  • 200 DMA₹35.73

Investment Returns

  • Over 1 Month -12.43%
  • Over 3 Month + 5.25%
  • Over 6 Month -9.45%
  • Over 1 Year -28.16%

Smart Investing Starts Here Start SIP with Parmax Pharma for Steady Growth!

Invest Now

Parmax Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -2.7
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 13
  • P/B Ratio
  • -2.3
  • Average True Range
  • 3.58
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.01
  • RSI
  • 50.96
  • MFI
  • 81.22

Parmax Pharma Financials

Parmax Pharma Technicals

EMA & SMA

Current Price
₹34.31
+ 1.75 (5.37%)
pointer
  • Bearish Moving Average 4
  • Bullish Moving Average 12
  • 20 Day
  • ₹33.92
  • 50 Day
  • ₹33.83
  • 100 Day
  • ₹34.24
  • 200 Day
  • ₹35.73

Resistance and Support

34.29 Pivot Speed
  • R3 35.12
  • R2 34.84
  • R1 34.57
  • S1 34.02
  • S2 33.74
  • S3 33.47

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Parmax Pharma has an operating revenue of Rs. 15.58 Cr. on a trailing 12-month basis. An annual revenue growth of 154% is outstanding, Pre-tax margin of -8% needs improvement, NULL From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 39 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 87 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Parmax Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-14 Quarterly Results
2025-08-14 Quarterly Results
2025-05-30 Audited Results
2025-02-14 Quarterly Results
2024-11-14 Quarterly Results

Parmax Pharma F&O

Parmax Pharma Shareholding Pattern

30.8%
63.08%
6.12%

About Parmax Pharma

  • NSE Symbol
  • PARMAX
  • BSE Symbol
  • 540359
  • Managing Director
  • Dr. Umang Alkesh Gosalia
  • ISIN
  • INE240T01014

Similar Stocks to Parmax Pharma

Parmax Pharma FAQs

Parmax Pharma share price is ₹34 As on 10 February, 2026 | 20:50

The Market Cap of Parmax Pharma is ₹12.8 Cr As on 10 February, 2026 | 20:50

The P/E ratio of Parmax Pharma is -2.7 As on 10 February, 2026 | 20:50

The PB ratio of Parmax Pharma is -2.3 As on 10 February, 2026 | 20:50

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23